Home

BVF I GP LLC

CIK 1803805 · last filed 2025-01-14

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$191.02M

Companies

10

Total Filings

14

Lifetime Open-Market Net

$618.09M

Filer Profile

Reported Address
44 MONTGOMERY ST., 40TH FLOOR
SAN FRANCISCO, CA 94104
Phone
(415) 525-8830
State of Incorporation
DE
Related Filers
BVF GP HOLDINGS LLC — 159 joint filings, latest 2026-07-16
BVF II GP LLC — 159 joint filings, latest 2026-07-16
BIOTECHNOLOGY VALUE FUND II LP — 155 joint filings, latest 2026-07-16
BIOTECHNOLOGY VALUE FUND L P — 155 joint filings, latest 2026-07-16
BVF INC/IL — 155 joint filings, latest 2026-07-16
BVF PARTNERS L P/IL — 155 joint filings, latest 2026-07-16
BVF Partners OS Ltd. — 155 joint filings, latest 2026-07-16
Biotechnology Value Trading Fund OS LP — 155 joint filings, latest 2026-07-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OLMA Director 2,103,522 $8.75 $18.41M $0 1 2025-01-14
FDMT 87,911 $14.47 $1.27M $0 1 2024-11-13
CGEM 392,808 $14.81 $5.82M $100.64M 2 2023-01-19
RAIN Director 1,367,838 $1.00 $1.37M $190.50M 2 2022-11-10
KYMR Director 1,466,364 $111.95 $164.16M $151.66M 2 2022-05-09
INFINITY PHARMACEUTICALS, INC. (INFI) Delisted 534,847 $0.04 $23.9K -$121.33M 1 2021-02-16
Merus N.V. (MRUS) Delisted 10%+ Owner 382,784 $90.00 $34.45M $230.43M 2 2020-12-22
CRESCENT BIOPHARMA, INC. (GLYC) Delisted 10%+ Owner 37,124 $15.70 $582.8K $32.94M 1 2020-11-06
FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted 10%+ Owner 541,084 $38.00 $20.56M $12.04M 1 2020-05-18
XOMA Royalty Corp (XOMA) Delisted 10%+ Owner 1,335,192 $40.17 $53.63M $21.22M 1 2020-03-17

Recent Filings · Page 2 of 2

14 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-11-06 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Buy (P) +12,667,370 $32.94M EDGAR
2020-06-03 Merus N.V. (MRUS) Delisted Buy (P) +14,625,100 $204.75M EDGAR
2020-05-18 FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted Buy (P) +2,935,870 $12.04M EDGAR
2020-03-17 XOMA Royalty Corp (XOMA) Delisted Buy (P) +1,182,770 $21.22M EDGAR
Showing 11–14 of 14
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.